双参数与多参数MRI诊断前列腺癌:PRIME诊断性临床试验
PRIME是一项前瞻性、多中心、患者内非劣效性试验,纳入22个中心(12个国家)的活检初治疑似前列腺癌男性。双参数MRI(省略钆对比剂序列)在诊断临床显著前列腺癌方面非劣效于多参数MRI,检出率分别为29.2%与29.6%(差值-0.4个百分点,95%CI -1.2至0.4,P=0.50)。
要点
- 双参数MRI诊断临床显著前列腺癌非劣效于多参数MRI,差值-0.4个百分点(95%CI -1.2至0.4)。
- 双参数MRI检出临床不显著癌9.2%,多参数MRI为9.6%(差值-0.4个百分点)。
- 在图像质量充分的前提下,双参数MRI联合或不联合靶向活检可能成为新的标准诊断路径。
核心结论
- 在疑似前列腺癌男性中,若图像质量充分,简化的双参数MRI联合或不联合靶向活检可能成为前列腺癌诊断的新标准。
研究设计与样本
- 前瞻性、多中心、患者内非劣效性试验,纳入22个中心(12个国家)的活检初治疑似前列腺癌男性,研究时间为2022年4月至2023年9月,末次随访于2024年12月3日进行。
- 共招募555名男性,其中490名纳入主要结局分析;中位年龄65岁(IQR 59-70),中位PSA水平5.6 ng/mL(IQR 4.4-8.0),直肠指检异常者占12.7%。
- 参与者先接受双参数MRI(T2加权和扩散加权序列)报告,放射科医生对DCE序列设盲;揭盲后报告完整的多参数MRI(含T2加权、扩散加权和动态对比增强序列)。
- 若双参数MRI或多参数MRI提示临床显著前列腺癌,则行靶向活检联合或不联合系统活检。
主要发现
- 双参数MRI检出临床显著前列腺癌143/490例(29.2%),多参数MRI检出145/490例(29.6%),差值-0.4个百分点(95%CI -1.2至0.4,P=0.50),达到非劣效性。
- 双参数MRI检出临床不显著癌45/490例(9.2%),多参数MRI检出47/490例(9.6%),差值-0.4个百分点(95%CI -1.2至0.4)。
- 中心质量控制显示99%的扫描图像具有足够的诊断质量。
关键数值与推荐
- 主要结局为临床显著前列腺癌的检出比例,非劣效性界值为5%。
- 双参数MRI对比多参数MRI检出临床显著前列腺癌的差值为-0.4个百分点(95%CI -1.2至0.4),P=0.50,达到非劣效性。
临床怎么用
- 在图像质量充分的前提下,双参数MRI联合或不联合靶向活检可能成为前列腺癌诊断的新标准。
- 采用双参数MRI可提高扫描仪吞吐量并降低全球成本。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Multiparametric magnetic resonance imaging (MRI), with or without prostate biopsy, has become the standard of care for diagnosing clinically significant prostate cancer. Resource capacity limits widespread adoption. Biparametric MRI, which omits the gadolinium contrast sequence, is a shorter and cheaper alternative offering time-saving capacity gains for health systems globally. OBJECTIVE: To assess whether biparametric MRI is noninferior to multiparametric MRI for diagnosis of clinically significant prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: A prospective, multicenter, within-patient, noninferiority trial of biopsy-naive men from 22 centers (12 countries) with clinical suspicion of prostate cancer (elevated prostate-specific antigen [PSA] level and/or abnormal digital rectal examination findings) from April 2022 to September 2023, with the last follow-up conducted on December 3, 2024. INTERVENTIONS: Participants underwent multiparametric MRI, comprising T2-weighted, diffusion-weighted, and dynamic contrast-enhanced (DCE) sequences. Radiologists reported abbreviated biparametric MRI first (T2-weighted and diffusion-weighted), blinded to the DCE sequence. After unblinding, radiologists reported the full multiparametric MRI. Patients underwent a targeted biopsy with or without systematic biopsy if either biparametric MRI or multiparametric MRI was suggestive of clinically significant prostate cancer. MAIN OUTCOMES AND MEASURES: The primary outcome was the proportion of men with clinically significant prostate cancer. Secondary outcomes included the proportion of men with clinically insignificant cancer. The noninferiority margin was 5%. RESULTS: Of 555 men recruited, 490 were included for primary outcome analysis. Median age was 65 (IQR, 59-70) years and median PSA level was 5.6 (IQR, 4.4-8.0) ng/mL. The proportion of patients with abnormal digital rectal examination findings was 12.7%. Biparametric MRI was noninferior to multiparametric MRI, detecting clinically significant prostate cancer in 143 of 490 men (29.2%), compared with 145 of 490 men (29.6%) (difference, -0.4 [95% CI, -1.2 to 0.4] percentage points; P = .50). Biparametric MRI detected clinically insignificant cancer in 45 of 490 men (9.2%), compared with 47 of 490 men (9.6%) with the use of multiparametric MRI (difference, -0.4 [95% CI, -1.2 to 0.4] percentage points). Central quality control demonstrated that 99% of scans were of adequate diagnostic quality. CONCLUSION AND RELEVANCE: In men with suspected prostate cancer, provided image quality is adequate, an abbreviated biparametric MRI scan, with or without targeted biopsy, could become the new standard of care for prostate cancer diagnosis. With approximately 4 million prostate MRIs performed globally annually, adopting biparametric MRI could substantially increase scanner throughput and reduce costs worldwide. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04571840.
引用
- Ng ABCD, Asif A, Agarwal R, et al. Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis: The PRIME Diagnostic Clinical Trial. JAMA. 2025. PMID: 40928788. doi:10.1001/jama.2025.13722
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。